Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 530.93%.
Infravalorada
El PE más reciente de la empresa es -1750.98, en un rango percentil bajo de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 133.41M acciones, lo que supone una reducción del 5.32% con respecto al trimestre anterior.
En posesión de Ron Baron
El inversor estrella Ron Baron posee 1.19M acciones de este valor.
Menor actividad del mercado
La empresa está generando menos interés entre los inversores, con una relación de rotación de 20 días del %!.(string=-0.33)